- Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast TranscriptJan 23, 2024
- Leap Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Leap Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Leap Therapeutics Inc Acquires Flame Biosciences TranscriptJan 17, 2023
- Leap Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Leap Therapeutics Inc - R&D Day TranscriptJul 12, 2022
- Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call TranscriptJan 21, 2022
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call TranscriptSep 17, 2021
- Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Leap Therapeutics Inc DKN-01 Clinical Data Conference Call TranscriptMar 22, 2021
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptApr 23, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptAug 06, 2019
Leap Therapeutics Inc DKN-01 Clinical Data Conference Call Transcript
Good morning, and welcome to the Leap Therapeutics DKN-01 clinical data conference call. (Operator Instructions) Please be advised that today's conference may be recorded.
I will now turn the call over to Cynthia Sirard, Chief Medical Officer. Please go ahead.
Good morning, and welcome. This morning, I would like to introduce a couple of my colleagues who have joined me to help present the data. I have Dr. Jay Baum, who is Vice President and Head of Translational Medicine at Leap Therapeutics; as well as Dr. Rebecca Arend who is an Associate Professor at the University of Alabama at Birmingham O'Neal Comprehensive Cancer Center. She was also our principal investigator on the trial that we will discuss today.
DKK1 is a modulator of Wnt signaling that is overexpressed in many cancers, often leading to worse outcomes for patients. It's secreted mainly by tumor cells and known to promote cancer cell proliferation,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)